You just read:

Seqirus presents analysis reinforcing the safety and immunogenicity profiles of its MF59®-adjuvanted seasonal trivalent influenza vaccine in adults 65 years and older

News provided by

Seqirus

26 Aug, 2016, 17:21 BST